company background image
DRRX logo

DURECT NasdaqCM:DRRX Stock Report

Last Price

US$1.34

Market Cap

US$40.0m

7D

4.7%

1Y

-69.0%

Updated

27 Mar, 2024

Data

Company Financials +

DRRX Stock Overview

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs.

DRRX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

DURECT Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DURECT
Historical stock prices
Current Share PriceUS$1.34
52 Week HighUS$7.46
52 Week LowUS$0.47
Beta0.82
1 Month Change40.06%
3 Month Change124.49%
1 Year Change-68.98%
3 Year Change-93.23%
5 Year Change-79.22%
Change since IPO-99.07%

Recent News & Updates

Recent updates

Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Aug 08
Brokers Are Upgrading Their Views On DURECT Corporation (NASDAQ:DRRX) With These New Forecasts

Durect names ex-RBC Capital Markets executive as CFO

Jul 05

Is DURECT (NASDAQ:DRRX) A Risky Investment?

May 12
Is DURECT (NASDAQ:DRRX) A Risky Investment?

DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be

Mar 14
DURECT Corporation (NASDAQ:DRRX) Analysts Are More Bearish Than They Used To Be

DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 10
DURECT Corporation (NASDAQ:DRRX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Jan 08
Does DURECT (NASDAQ:DRRX) Have A Healthy Balance Sheet?

Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Aug 05
Is DURECT (NASDAQ:DRRX) Using Debt Sensibly?

Durect (DRRX) Investor Presentation - Slideshow

May 06

Durect EPS misses by $0.01, misses on revenue

May 04

DURECT prices ~$43M stock offering

Feb 04

DURECT surges after FDA approval for Posimir

Feb 02

Durect's DUR-928 fast track'd for alcoholic hepatitis in the U.S.

Dec 16

DURECT (DRRX) Investor Presentation - Slideshow

Oct 31

Shareholder Returns

DRRXUS PharmaceuticalsUS Market
7D4.7%1.2%0.4%
1Y-69.0%25.8%28.8%

Return vs Industry: DRRX underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.

Return vs Market: DRRX underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is DRRX's price volatile compared to industry and market?
DRRX volatility
DRRX Average Weekly Movement14.5%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: DRRX's share price has been volatile over the past 3 months.

Volatility Over Time: DRRX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199872Jim Brownhttps://www.durect.com

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

DURECT Corporation Fundamentals Summary

How do DURECT's earnings and revenue compare to its market cap?
DRRX fundamental statistics
Market capUS$39.97m
Earnings (TTM)-US$36.65m
Revenue (TTM)US$9.19m

4.3x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DRRX income statement (TTM)
RevenueUS$9.19m
Cost of RevenueUS$35.27m
Gross Profit-US$26.07m
Other ExpensesUS$10.58m
Earnings-US$36.65m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.23
Gross Margin-283.57%
Net Profit Margin-398.65%
Debt/Equity Ratio129.8%

How did DRRX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.